Mitsubishi UFJ Morgan Stanley Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$5K	Buy	+50	New	+$4.16K	0.01%	250
2013 Q4	–	Sell	-690	Closed	-$50K	–	247
2013 Q3	$50K	Buy	690 +90	+15%	+$5.98K	0.08%	66
2013 Q2	$33K	Buy	+600	New	+$37.4K	0.11%	114

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's BMRN Position: Q4 2014 in Review

Mitsubishi UFJ Morgan Stanley Securities opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2014: 50 shares worth $5K. The stake represents 0.01% of the portfolio and ranks #250 among its holdings. This is a return to the name: Mitsubishi UFJ Morgan Stanley Securities previously reported a position in BMRN as recently as Q3 2013.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in BMRN in Q2 2013 and has held it in 3 quarters since. The position peaked at $50K in Q3 2013. 341 funds tracked by Wall St. Rank hold BMRN as of Q4 2014.

Mitsubishi UFJ Morgan Stanley Securities held 50 shares of BioMarin Pharmaceuticals worth $5K as of Q4 2014.
BioMarin Pharmaceuticals was a new Mitsubishi UFJ Morgan Stanley Securities position in Q4 2014.
BioMarin Pharmaceuticals made up 0.01% of Mitsubishi UFJ Morgan Stanley Securities's portfolio in Q4 2014, its #250 holding.
Mitsubishi UFJ Morgan Stanley Securities first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 3 quarters since.
Mitsubishi UFJ Morgan Stanley Securities's BioMarin Pharmaceuticals position peaked at $50K in Q3 2013.
341 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2014.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q4 2014, filed 17 Feb 2015.